Evgen Pharma Share Discussion Threads

[stockhunters] 16/10/2020 15:54

just look at sng and the demand huge cash raise near share price highs

[moneymunch] 16/10/2020 15:48

Looks like a nice UPward surge into close is definitely on the cards....Gla ;-)))

[bumpa33] 16/10/2020 15:48

Ha - u beat me to it SH.

[bumpa33] 16/10/2020 15:45

I (more than) suspect we have a decent bid underpinning us today...

[stockhunters] 16/10/2020 15:45

large buyer continues to soak up the stock

[moneymunch] 16/10/2020 15:41

Along with Evgen's share price ....surely news on SFX-01's Covid-19 patient trials will be announced next week. Gla ;-)

[moneymunch] 16/10/2020 15:32

Scottish numbers: Continue to rise ;-(

16 October 2020

Summary

1,196 new cases of COVID-19 reported; this is 16.9%* of newly tested individuals
9 new reported death(s) of people who have tested positive
58 people were in intensive care yesterday with recently confirmed COVID-19
629 people were in hospital yesterday with recently confirmed COVID-19
21,057 new tests for COVID-19 that reported results

[bumpa33] 16/10/2020 11:17

mm - someone or some entity has/is already committing, they just don’t want anyone currently to know! I’ve given up on that line (of enquiry), we’ll know when we know.

[moneymunch] 16/10/2020 11:05

ps Bumpa, it's conceivable that any potential strategic investor/suitor would want the 20 year patent extension in place before committing??? ;-)

[moneymunch] 16/10/2020 11:00

They might show their hand in due course....let's see what transpires.....and perhaps the biggest piece of near term news, which has been overlooked , would be the 20 year patent extension.....confirmation news would be massive and would add significant UPside imho....Gl ;-)


15/6/20


INTELLECTUAL PROPERTY UPDATE

Our IP portfolio continues to be strengthened with a number of key patents being granted. The current status of the intellectual property portfolio is as follows:

-- From the "parent" patent family entitled "Stabilised Sulforaphane" patents are granted in Australia, Canada, EU, US, Japan and Hong Kong.

-- The principal manufacturing patent application, entitled "Methods of Synthesising Sulforaphane" is granted in Australia, China, Europe, Japan and further applications are pending in Brazil, Canada, US and India.

-- A second manufacturing patent which is directed to methods of isolating and purifying sulforaphane or analogues from natural sources has been granted in Europe, US, Japan and China.

-- The patent application providing protection around novel analogues based on sulforaphane, and entitled "Sulforaphane-Derived Compounds" is granted in Australia, China, Europe, Japan and the US and pending in Canada.

During the year composition of matter SFX-01 patents were granted both in Japan and Europe with a product claim for a complex of sulforaphane and alpha-cyclodextrin. The Group has long held broad compositional patent protection in the United States since patent grant in 2011 and in Canada since grant in 2014.

Furthermore, new composition of matter filings have been made which, if successful, would add a further 20 years of patent life to the key patent family.

[carlisle44] 16/10/2020 10:57

Thank you for the replies . A couple of ticks North this morning. I remain patient

GLA

[bumpa33] 16/10/2020 10:53

mm - i suspect we’re not going to get any further TR1’s. The who or the why wants to stay under the radar.

[moneymunch] 16/10/2020 10:50

News on the status of the Covid-19 trial surely must be imminent, and plenty of other news on the rest of the pieline must be close. SFX-01 has been in evaluation for multiple disease targets for clinical trials from several academic research organisations since the start of the year and so news could drop at anytime, as well as the high profile breat cancer research, which is now in the planning for phase 2b trials with Manchester Unversity, and the following outlines the planned work programme and so news on the progress very likely. I aslo think there is a high chance of news on a strategic investor or early commercial JV which would certainly explain the massive share transfer/accumulation over several months or at least a TR1 at the very least with disclosure of who or why!!!??? Gl ;-)


.........

Breast Cancer Current and planned work programme

All preclinical breast data published in high impact journal in June 2020

Extensive review of clinical pathway to approval close to completion

Supplementary preclinical work required to confirm CDK4/6i “resistance-breaking” hypothesis

New “commercial ready” solid tablet formulation to be completed in H3 2020

Non-dilutive capital e.g. partnering to fund the next trial(s)

Targeting CTA/IND in H1 2021 with first patient first dose in Q2/Q3 2021

[bumpa33] 16/10/2020 10:40

Yep C44, impossible to say really - but we’ve waited quite a while for the trials to begin - so now is the time patience hopefully pays off. There is huge headroom (for the sp) if we get positive indications...

[enter] 16/10/2020 10:33

It's hard to have a timetable but you would think with there being more and more hospital patients that news must be very close now.

[carlisle44] 16/10/2020 10:14

Hoping to see a major spike up here but there again have been holding expecting news for quite some time. Anyone have a realistic timetable to News?

TIA

[bumpa33] 16/10/2020 10:03

Well, we’re in the sweet spot now and you have to be in it to win it :) So let’s see...

[moneymunch] 16/10/2020 09:49

I reckon we should have a good day today from those anticapating news this coming week, the chart couldn't looked more primed for the next leg UP. ;-)

[moneymunch] 16/10/2020 09:45

Yep, co-investigator of SFX-01's Covid-19 patient trials and a listed Consultant to Evgen, and her life's work focussed on Sulforaphane and Nrf2....more than a vested interest. ;-)

[bumpa33] 16/10/2020 09:38

I’m sure Dinkova will be keeping EVG in the loop mm :)

[moneymunch] 16/10/2020 09:02

Morning Bumpa, i had noticed that myself, initially i was expecting Prof Chalmers as the lead investigator to announce confirmation that first patients had been administered, although perhaps the new CEO will now be to given responsibility to confirm via RNS, to give the share price and market interest a boost.....it was hardly satisfactory imho when news of LifArc's funding for the trial was known before Evgen confirmed the fact by RNS the next day ( a great find by you, nevertheless ), which allowed punters to buy in before the news and then sell into the rise which put a dampner and diluted what should have been major news in normal circumstances. Fingers crossed for an UPdate on proceedings next week from the new CEO. Gl ;-)

[bumpa33] 16/10/2020 08:45

mm - our man Mr Chalmers has gone quiet on Twitter the last few days. Must be a busy man these days...

[stockhunters] 16/10/2020 07:45

lockdowns nationwide

unfortunately stocks like EVG will be the most sort after as covid trials take a step up

[moneymunch] 16/10/2020 07:26

SFX-01's Covid-19 patient trial is phase 2/3 which is "Phase 2 and 3 Combination Design to Accelerate Drug Development ", we already know that SFX-01's safety profile is safe and sound from SFX-01's phase 2 SAH and SFX-01's phase 2 breast cancer trials, and so if an early therapeutic benfit is observed in the Covid-19 trials, then presumably the trial will be accelerated into phase 3.......Top Line results are expected September 2021, but no doubt early reporting will be made on any positive indications from the phase 2 stage of the trial.......news next week that the trial is already in progress would be very well received. Gla ;-)

"with patients offered the chance to participate immediately after their diagnosis"

The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

[enter] 15/10/2020 17:18

There's no doubt the number of people in hospital with COVID-19 is rising all the time, particularly in the north of England and Scotland. Hopefully Professor Chalmers and Professor Kostova are talking to the right people and getting patients enrolled.